Incidence and risk factors for gadolinium-based contrast agent immediate reactions

James R. Costello, Bobby T Kalb, Diego R Martin

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Since their clinical introduction in 1988, gadolinium-based contrast agents (GBCAs) have demonstrated an excellent safety profile with a reported acute adverse reaction rate ranging from 0.01% to 2%. By comparison, the acute adverse reaction rate of low osmolar nonionic computed tomography contrast agents (CTCs) ranges from 0.7% to 3.1%. Many of the risk factors associated with CTC reactions (drug allergies, asthma, atopy, prior contrast reaction) also point toward an increased incidence of acute adverse events to GBCAs.With CTCs, an increased adverse event rate was associated with ionic preparations and high osmolality. In response to concerns for nephrogenic systemic fibrosis, GBCAs are now selected for their augmented chemical stability. These agents possess some combination of macrocyclic chelates or ionic preparations. With their improved chemical stability, these agents also possess higher osmolality and the increased potential to elicit an acute adverse reaction. In light of these concerns, researchers are now focusing greater efforts on reexamining acute adverse reactions to GBCAs and whether there is an increased association with certain agents. In addition to hypersensitivity reactions, this article will also discuss contrast extravasations, safety of GBCAs for pregnant and nursing patients, and the potential nephrotoxic effects of GBCAs.

Original languageEnglish (US)
Pages (from-to)257-263
Number of pages7
JournalTopics in Magnetic Resonance Imaging
Volume25
Issue number6
DOIs
StatePublished - 2016

Fingerprint

Gadolinium
Contrast Media
Incidence
Osmolar Concentration
Nephrogenic Fibrosing Dermopathy
Safety
Drug Hypersensitivity
Hypersensitivity
Nursing
Asthma
Tomography
Research Personnel

Keywords

  • Acute Adverse Reactions
  • Contrast Extravasation
  • Contrast Nephrotoxicity
  • Gadolinium-Based Contrast Agents
  • Immunologic Mechanism For Contrast Reaction

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Incidence and risk factors for gadolinium-based contrast agent immediate reactions. / Costello, James R.; Kalb, Bobby T; Martin, Diego R.

In: Topics in Magnetic Resonance Imaging, Vol. 25, No. 6, 2016, p. 257-263.

Research output: Contribution to journalReview article

@article{d645f07832cc4e91a259b8cd6d059974,
title = "Incidence and risk factors for gadolinium-based contrast agent immediate reactions",
abstract = "Since their clinical introduction in 1988, gadolinium-based contrast agents (GBCAs) have demonstrated an excellent safety profile with a reported acute adverse reaction rate ranging from 0.01{\%} to 2{\%}. By comparison, the acute adverse reaction rate of low osmolar nonionic computed tomography contrast agents (CTCs) ranges from 0.7{\%} to 3.1{\%}. Many of the risk factors associated with CTC reactions (drug allergies, asthma, atopy, prior contrast reaction) also point toward an increased incidence of acute adverse events to GBCAs.With CTCs, an increased adverse event rate was associated with ionic preparations and high osmolality. In response to concerns for nephrogenic systemic fibrosis, GBCAs are now selected for their augmented chemical stability. These agents possess some combination of macrocyclic chelates or ionic preparations. With their improved chemical stability, these agents also possess higher osmolality and the increased potential to elicit an acute adverse reaction. In light of these concerns, researchers are now focusing greater efforts on reexamining acute adverse reactions to GBCAs and whether there is an increased association with certain agents. In addition to hypersensitivity reactions, this article will also discuss contrast extravasations, safety of GBCAs for pregnant and nursing patients, and the potential nephrotoxic effects of GBCAs.",
keywords = "Acute Adverse Reactions, Contrast Extravasation, Contrast Nephrotoxicity, Gadolinium-Based Contrast Agents, Immunologic Mechanism For Contrast Reaction",
author = "Costello, {James R.} and Kalb, {Bobby T} and Martin, {Diego R}",
year = "2016",
doi = "10.1097/RMR.0000000000000109",
language = "English (US)",
volume = "25",
pages = "257--263",
journal = "Topics in Magnetic Resonance Imaging",
issn = "0899-3459",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Incidence and risk factors for gadolinium-based contrast agent immediate reactions

AU - Costello, James R.

AU - Kalb, Bobby T

AU - Martin, Diego R

PY - 2016

Y1 - 2016

N2 - Since their clinical introduction in 1988, gadolinium-based contrast agents (GBCAs) have demonstrated an excellent safety profile with a reported acute adverse reaction rate ranging from 0.01% to 2%. By comparison, the acute adverse reaction rate of low osmolar nonionic computed tomography contrast agents (CTCs) ranges from 0.7% to 3.1%. Many of the risk factors associated with CTC reactions (drug allergies, asthma, atopy, prior contrast reaction) also point toward an increased incidence of acute adverse events to GBCAs.With CTCs, an increased adverse event rate was associated with ionic preparations and high osmolality. In response to concerns for nephrogenic systemic fibrosis, GBCAs are now selected for their augmented chemical stability. These agents possess some combination of macrocyclic chelates or ionic preparations. With their improved chemical stability, these agents also possess higher osmolality and the increased potential to elicit an acute adverse reaction. In light of these concerns, researchers are now focusing greater efforts on reexamining acute adverse reactions to GBCAs and whether there is an increased association with certain agents. In addition to hypersensitivity reactions, this article will also discuss contrast extravasations, safety of GBCAs for pregnant and nursing patients, and the potential nephrotoxic effects of GBCAs.

AB - Since their clinical introduction in 1988, gadolinium-based contrast agents (GBCAs) have demonstrated an excellent safety profile with a reported acute adverse reaction rate ranging from 0.01% to 2%. By comparison, the acute adverse reaction rate of low osmolar nonionic computed tomography contrast agents (CTCs) ranges from 0.7% to 3.1%. Many of the risk factors associated with CTC reactions (drug allergies, asthma, atopy, prior contrast reaction) also point toward an increased incidence of acute adverse events to GBCAs.With CTCs, an increased adverse event rate was associated with ionic preparations and high osmolality. In response to concerns for nephrogenic systemic fibrosis, GBCAs are now selected for their augmented chemical stability. These agents possess some combination of macrocyclic chelates or ionic preparations. With their improved chemical stability, these agents also possess higher osmolality and the increased potential to elicit an acute adverse reaction. In light of these concerns, researchers are now focusing greater efforts on reexamining acute adverse reactions to GBCAs and whether there is an increased association with certain agents. In addition to hypersensitivity reactions, this article will also discuss contrast extravasations, safety of GBCAs for pregnant and nursing patients, and the potential nephrotoxic effects of GBCAs.

KW - Acute Adverse Reactions

KW - Contrast Extravasation

KW - Contrast Nephrotoxicity

KW - Gadolinium-Based Contrast Agents

KW - Immunologic Mechanism For Contrast Reaction

UR - http://www.scopus.com/inward/record.url?scp=84991467052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991467052&partnerID=8YFLogxK

U2 - 10.1097/RMR.0000000000000109

DO - 10.1097/RMR.0000000000000109

M3 - Review article

VL - 25

SP - 257

EP - 263

JO - Topics in Magnetic Resonance Imaging

JF - Topics in Magnetic Resonance Imaging

SN - 0899-3459

IS - 6

ER -